CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients

Completed

• Conditions: Presence of COVID-19 Compatible CT Abnormalities

• Registration Number: NCT04512118
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

CT signs that are evocative of lung COVID-19 infections have been extensively described, whereas 18F-FDG-PET signs have not. Our current study aimed to identify specific COVID-19 18F-FDG-PET signs in patients that were (i) suspected to have a lung infection based on 18F-FDG-PET/CT recorded during the COVID-19 outbreak and (ii) whose COVID-19 diagnosis was definitely established or excluded by appropriate viral testing.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-15
• Primary Completion: 2020-06-30
• Study Completion: 2020-07-30
• Status Verified: 2020-08
• Study First Submitted: 2020-08-12
• Study First Submitted QC: 2020-08-12
• Last Update Submitted: 2020-08-12
• Study First Posted: 2020-08-13
• Last Update Posted: 2020-08-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Patient coming to nuclear medicine for 18F-flurodesoxyglucose (FDG) positron emission tomography computed tomography (PET-CT) with suspicion of lung involvement
• patient affiliated to a social security scheme or equivalent
• adult patient having been informed of the study

Exclusion Criteria

• patient with a negative covid 19 test

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Visual analysis of pulmonary lobes	1 day	Visual analysis of the pulmonary lobes by calculating a extent score for each patient

Secondary Outcome Measures

Name	Time	Method
Measurement of metabolic activity	1 day	Measurement of metabolic activity with SUV max of lung areas with CT abnormalities

Trial Locations

Locations (1)

CHRU of Nancy; 🇫🇷 Vandœuvre-lès-Nancy, Grand Est, France